NO911602L - Immunogent aktive fraksjoner av borrelia burgdorferi. - Google Patents

Immunogent aktive fraksjoner av borrelia burgdorferi.

Info

Publication number
NO911602L
NO911602L NO91911602A NO911602A NO911602L NO 911602 L NO911602 L NO 911602L NO 91911602 A NO91911602 A NO 91911602A NO 911602 A NO911602 A NO 911602A NO 911602 L NO911602 L NO 911602L
Authority
NO
Norway
Prior art keywords
burgdorferi
fractions
cells
active fractions
sera
Prior art date
Application number
NO91911602A
Other languages
English (en)
Other versions
NO911602D0 (no
Inventor
Sven Bergstroem
Alan G Barbour
Louis A Magnarelli
Original Assignee
Symbicom Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symbicom Ab filed Critical Symbicom Ab
Publication of NO911602D0 publication Critical patent/NO911602D0/no
Publication of NO911602L publication Critical patent/NO911602L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Nye, immunogent aktive frak- sjoner B, C og E fra Borrelia burg- dorferi kan erholdes ved hjelp av en fremgangsmåte som omfatter som et første trinn å lysere B. burgdorferi spiroketceller med en mild, ikke- denaturerende detergent, f.eks. octyl- (3-D-glucopyranosid, for å frigjøre yttermembran- og cytoplasmakomponenter fra cellene. Fraksjonene er i det vesentlige frie for cellevegg- og flagellkomponenter fra B. burgdorferi, f.eks. frie for flagellin, og har i det vesentlige den samme reaktivitet med sera fra pasienter med Lyme-sykdom som helceller av B. burgdorferi, men' med vesentlig mindre reaktivitet med sera fra syfilispasienter. Fraksjonene, særlig fraksjon B, kan anvendes til immunisering mot og diagnose av Lyme- sykdom. Det er også beskrevet et DNA- fragment som koder for et antigent polypeptid som er beslektet med ytter- membranproteinet OspA.
NO91911602A 1988-10-24 1991-04-23 Immunogent aktive fraksjoner av borrelia burgdorferi. NO911602L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser
PCT/DK1989/000248 WO1990004411A1 (en) 1988-10-24 1989-10-24 Immunogenically active fractions of borrelia burgdorferi

Publications (2)

Publication Number Publication Date
NO911602D0 NO911602D0 (no) 1991-04-23
NO911602L true NO911602L (no) 1991-06-24

Family

ID=8146053

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91911602A NO911602L (no) 1988-10-24 1991-04-23 Immunogent aktive fraksjoner av borrelia burgdorferi.

Country Status (10)

Country Link
US (6) US5523089A (no)
EP (4) EP0445135B1 (no)
AT (3) ATE432988T1 (no)
AU (1) AU639667B2 (no)
CA (1) CA2001328C (no)
DE (4) DE68929565D1 (no)
DK (3) DK590288D0 (no)
FI (1) FI112366B (no)
NO (1) NO911602L (no)
WO (1) WO1990004411A1 (no)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054296A (en) 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US6300101B1 (en) * 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
ZA907419B (en) * 1989-09-19 1991-07-31 Max Planck Gesellschaft Vaccine against lyme disease
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5470712A (en) * 1990-03-05 1995-11-28 Us Health Antigenic proteins of Borrelia burgdorferi
SG47447A1 (en) * 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US5436000A (en) * 1991-01-11 1995-07-25 University Of Texas System Flagella-less borrelia
AU2247192A (en) * 1991-06-13 1993-01-12 Pacific Biotech, Inc. Assay for the detection of specific ligands
US5324630A (en) * 1991-06-28 1994-06-28 The Regents Of The University Of California Methods and compositions for diagnosing lyme disease
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
DE69229476T2 (de) * 1991-08-15 2000-03-16 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
ATE234365T1 (de) * 1991-10-22 2003-03-15 Symbicom Ab Verbesserungen der diagnose und der prophylaxe von borrelia burgdorferi
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5308753A (en) * 1992-02-20 1994-05-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for purifying and detecting IGM antibodies
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
BE1006728A3 (fr) * 1993-02-19 1994-11-29 Wallone Region Sondes d'acides nucleiques specifiques au spirochete borrelia burgdorferi.
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
ES2265643T3 (es) * 1994-04-11 2007-02-16 Wyeth Holdings Corporation Bacteria de borrelia burgdorferi.
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
US6312907B1 (en) 1995-04-24 2001-11-06 The Texas A & M University System DbpA compositions and methods of use
US6214355B1 (en) 1995-04-24 2001-04-10 Texas A & M University System DbpA compositions
US6248517B1 (en) 1995-04-24 2001-06-19 The Texas A & M University System Decorin binding protein compositions and methods of use
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
EP0832220A1 (en) * 1995-06-07 1998-04-01 Amgen Inc. Ob protein compositions and method
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
EP0915977A1 (en) * 1996-05-08 1999-05-19 Yale University B. burgdorferi polypeptides expressed in vivo
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
DE19632862B4 (de) * 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
WO1998058943A1 (en) * 1997-06-20 1998-12-30 Human Genome Sciences, Inc. Borrelia burgdorferi polynucleotides and sequences
US6902893B1 (en) 1997-06-20 2005-06-07 Gil H. Choi Lyme disease vaccines
AU8177298A (en) * 1997-06-30 1999-01-19 The Administrators Of The Tulane Eductional Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
EP1012269A2 (en) * 1997-09-10 2000-06-28 Symbicom Ab P13 antigens from borrelia
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
WO2000078345A1 (en) * 1999-06-21 2000-12-28 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6689364B2 (en) 2000-03-21 2004-02-10 Tufts University Borrelia burgdorferi polypeptides and uses thereof
WO2001092870A2 (de) * 2000-06-02 2001-12-06 Zeptosens Ag Kit und verfahren zur multianalytbestimmung
EP1311540B1 (en) * 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
US20040033623A1 (en) * 2002-08-16 2004-02-19 Igenex, Inc. Assay for detection of antigen in bodily fluid
WO2004103269A2 (en) * 2002-10-18 2004-12-02 Macrogenics, Inc. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP2030979A1 (en) * 2003-04-02 2009-03-04 The Government of the United States of America as Represented by The Department of Health and Human Services Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
US20060051060A1 (en) * 2003-07-03 2006-03-09 Henry Dorovanessian Method and system for digitally recording broadcast content
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US20060281139A1 (en) * 2005-05-23 2006-12-14 Viramed Biotech Ag Carrier and method for the detection of anti-borrelia antibodies and test kit for use in the diagnosis of Lyme borreliosis infections
US7663212B2 (en) 2006-03-21 2010-02-16 Infineon Technologies Ag Electronic component having exposed surfaces
US7541681B2 (en) * 2006-05-04 2009-06-02 Infineon Technologies Ag Interconnection structure, electronic component and method of manufacturing the same
BRPI0719360B1 (pt) 2006-11-03 2016-09-06 Intervet Int Bv vacina da doença de lyme canina, e, uso de organismos de uma genoespécie de borrelia
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US20110117131A1 (en) * 2008-04-09 2011-05-19 Ning Huang Production of OspA for Lyme Disease Control
EP2711021B1 (en) 2008-05-02 2016-03-09 BliNK Therapeutics Limited Products and methods for stimulating an immune response
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
EA025280B1 (ru) 2010-03-09 2016-12-30 Амир Максютов Полиэпитопные конструкции и способы их получения и применения
KR20180082633A (ko) 2010-05-14 2018-07-18 박스알타 인코퍼레이티드 Ｏｓｐａ 키메라 및 백신에서 그의 용도
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
CN103229055A (zh) 2010-09-27 2013-07-31 康奈尔大学 莱姆病的诊断方法
WO2012047970A1 (en) * 2010-10-05 2012-04-12 Board Of Trustees Of Michigan State University Regulatory factors controlling oil biosynthesis in microalgae and their use
CN104640563A (zh) 2012-07-27 2015-05-20 巴克斯特国际公司 包含嵌合的ospa分子的组合物及其使用方法
US10669567B2 (en) 2015-02-17 2020-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High sensitivity method for early Lyme disease detection
EP3442587B1 (en) 2016-04-14 2021-08-18 Boehringer Ingelheim Animal Health USA Inc. Multi-dose compositions containing an antimicrobial polyamide or octenidine preservative
WO2018227109A1 (en) 2017-06-08 2018-12-13 Colorado State University Research Foundation Differentiation of lyme disease and southern tick-associated rash illness
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4888276A (en) 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) * 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit

Also Published As

Publication number Publication date
US6203798B1 (en) 2001-03-20
EP1092774A2 (en) 2001-04-18
EP1092774B1 (en) 2009-06-03
ATE432988T1 (de) 2009-06-15
DE68929369T2 (de) 2002-09-26
DE68927891T2 (de) 1997-10-02
FI911964A0 (fi) 1991-04-23
DK200401413A (da) 2004-09-17
DK75091A (da) 1991-06-12
DK590288D0 (da) 1988-10-24
ATE212376T1 (de) 2002-02-15
NO911602D0 (no) 1991-04-23
EP0445135A1 (en) 1991-09-11
DE68927891D1 (de) 1997-04-24
DK175844B1 (da) 2005-03-29
DE68929369D1 (de) 2002-03-14
US5688512A (en) 1997-11-18
EP0565208A1 (en) 1993-10-13
EP0711563B1 (en) 2007-01-17
FI112366B (fi) 2003-11-28
US5523089A (en) 1996-06-04
US6083722A (en) 2000-07-04
DK75091D0 (da) 1991-04-23
US6183986B1 (en) 2001-02-06
CA2001328A1 (en) 1991-04-24
WO1990004411A1 (en) 1990-05-03
ATE150318T1 (de) 1997-04-15
DE68929565D1 (de) 2009-07-16
US5582990A (en) 1996-12-10
DE68929550T2 (de) 2007-12-06
AU639667B2 (en) 1993-08-05
DE68929550D1 (de) 2007-03-08
AU4495389A (en) 1990-05-14
CA2001328C (en) 2005-12-13
EP0445135B1 (en) 1997-03-19
EP1092774A3 (en) 2001-04-25
EP0565208B1 (en) 2002-01-23
EP0711563A1 (en) 1996-05-15

Similar Documents

Publication Publication Date Title
NO911602L (no) Immunogent aktive fraksjoner av borrelia burgdorferi.
DK489581A (da) Praeparat til terapeutisk eller diagnostisk anvendelse og fremgangsmaade til terapeutisk behandling
Kalish et al. Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease
JP5390189B2 (ja) 多価キメラｏｓｐｃワクシノーゲンおよび診断用抗原
Miller et al. Temporal Analysis of Borrelia burgdorferi Erp Protein Expression throughout the Mammal-Tick InfectiousCycle
Dale et al. Epitopes of streptococcal M proteins shared with cardiac myosin.
Earnhart et al. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences
Luft et al. Immunologic and structural characterization of the dominant 66-to 73-kDa antigens of Borrelia burgdorferi.
DK0650527T3 (da) Forbedring af Borrelia burgdorferidiagnose og -profylakse
NO995002D0 (no) Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF-<alfa>-molekyler og DNA
ATE348165T1 (de) Peptide und nachweis zur diagnose von lyme- krankheit und zusammensetzungen zu deren verhütung
EP1012181B1 (en) Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
DK1100922T3 (da) Anvendelser af én eller flere borreliacide epitoper på ydermembranprotein C fra Borrelia burgdorferi (OspC) som vaccine
WO1997042221A1 (en) Novel osp-c derived peptide fragments
Noppa et al. P13, an integral membrane protein of Borrelia burgdorferi, is C-terminally processed and contains surface-exposed domains
DE69531345D1 (de) Rekombinant pgp3, verfahren zu dessen herstellung, und dessen verwendung in der diagnose und therapie
US6716574B2 (en) Osp-C derived peptide fragments
EP3029073B1 (en) Polyvalent chimeric ospc vaccinogen and diagnostic antigen
CN101374858A (zh) 多价嵌合ospc疫苗原及诊断抗原
Amoudy et al. Demonstration of in vivo expression of a hypothetical open reading frame (ORF‐14) encoded by the RD1 region of Mycobacterium tuberculosis
Rauer et al. Recombinant low-molecular-mass proteins pG and LA7 from Borrelia burgdorferi reveal low diagnostic sensitivity in an enzyme-linked immunosorbent assay
Griskevicius et al. Prevalence of B. burgdorferi stains by applying the microgen immunoblots
McKinney et al. Diethylaminoethyl-cellulose-bacterial cell immunoadsorbent columns: preparation of serotype-specific globulin and immunofluorescent conjugates for Streptococcus mutans serotypes a and d
TW387012B (en) Recombitope peptides